Pharmaceutical Technology

SEPTEMBER 30, 2022

Shortly after this, the FDA announced the accelerated approval of bluebird's Skysona (elivaldogene autotemcel), or eli-cel, on 19 September. Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye.

FDA 115

FDA Insurance 115

STAT

OCTOBER 6, 2022

million tag as cost effective for a Bluebird Bio drug called Zynteglo for the blood disorder beta thalassemia, Arbuckle said in an interview. Bluebird also recently said it would charge $3 million for Skysona, the gene therapy it just launched for a rare brain-wasting disease. Continue to STAT+ to read the full story…

74

74

pharmaphorum

JUNE 12, 2022

Beti-cel has already been approved for marketing in Europe as Zynteglo, with a price tag of around $1.8 Eli-cel was also previously approved in Europe as Skysona. million price tag, saying its ability to help patients reach sustained transfusion independence justified its high price.

FDA 59

FDA 59